Table of Contents
Molecular Biology International
Volume 2012 (2012), Article ID 648512, 4 pages
http://dx.doi.org/10.1155/2012/648512
Editorial

Host-Pathogen Interactions of Retroviruses

1Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
2Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA
3Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
4Center for Virology, Burnet Institute, Melbourne, VIC 3004, Australia
5Department of Microbiology, Monash University, Clayton, VIC 3168, Australia
6Department of Medicine, Monash University, Melbourne, VIC 3004, Australia

Received 30 August 2012; Accepted 30 August 2012

Copyright © 2012 Abdul A. Waheed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Brass, D. M. Dykxhoorn, Y. Benita et al., “Identification of host proteins required for HIV infection through a functional genomic screen,” Science, vol. 319, no. 5865, pp. 921–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. R. König, Y. Zhou, D. Elleder et al., “Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication,” Cell, vol. 135, no. 1, pp. 49–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. L. Yeung, L. Houzet, V. S. R. K. Yedavalli, and K. T. Jeang, “A genome-wide short hairpin RNA screening of Jurkat T-cells for human proteins contributing to productive HIV-1 replication,” The Journal of Biological Chemistry, vol. 284, no. 29, pp. 19463–19473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ashkenazi, Y. Wexler-Cohen, and Y. Shai, “Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor,” Biochimica et Biophysica Acta, vol. 1808, no. 10, pp. 2352–2358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Chen, P. Zhan, E. De Clercq, and X. Liu, “Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors,” Current Pharmaceutical Design, vol. 18, pp. 100–112, 2012. View at Google Scholar
  6. T. Cihlar and A. S. Ray, “Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine,” Antiviral Research, vol. 85, no. 1, pp. 39–58, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. K. Quashie, R. D. Sloan, and M. A. Wainberg, “Novel therapeutic strategies targeting HIV integrase,” BMC Medicine, vol. 10, article 34, 2012. View at Google Scholar
  8. M. Estebanez and J. R. Arribas, “Protease inhibitor monotherapy: what is its role?” Current HIV/AIDS Reports, vol. 9, pp. 179–185, 2012. View at Google Scholar
  9. R. W. Burgoyne and D. H. S. Tan, “Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 3, pp. 469–473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Michaud, T. Bar-Magen, J. Turgeon, D. Flockhart, Z. Desta, and M. A. Wainberg, “The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition,” Pharmacological Reviews, vol. 64, pp. 803–833, 2012. View at Google Scholar
  11. C. B. Hurt, J. J. Eron Jr., and M. S. Cohen, “Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?” Clinical Infectious Diseases, vol. 53, pp. 1265–1270, 2011. View at Google Scholar